Christopher Astle serves as Executive at Zymeworks Inc., where they oversee executive responsibilities. Since joining the company, Christopher Astle has executed 9 insider transactions totaling $83.4K, demonstrating a bearish approach to their equity position. Their most recent transaction on Jan 8, 2024 involved selling 1,431 shares valued at $16.1K.
Christopher Astle currently holds 6,503 shares of Zymeworks Inc. (ZYME), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Christopher Astle has been a net seller of ZYME stock. They have purchased $0 and sold $83.4K worth of shares.
Christopher Astle's most recent insider trade was on Jan 8, 2024, when they sold 1,431 shares at $11.22 per share.
Get notified when new Form 4 filings are submitted
| $10.65 |
| Discretionary |
| Jan 5, 2024 | ZYME | $0 | Option Exercise | 10,500 | $N/A | Discretionary |
| Dec 11, 2023 | ZYME | $0 | Option Exercise | 1,550 | $N/A | Discretionary |
| Dec 11, 2023 | ZYME | $8.1K | Sale | 886 | $9.13 | Discretionary |
| Dec 12, 2022 | ZYME | $0 | Option Exercise | 1,550 | $N/A | Discretionary |
| Dec 12, 2022 | ZYME | $5.3K | Sale | 887 | $6.01 | Discretionary |
| Dec 12, 2022 | ZYME | $0 | Option Exercise | 1,550 | $N/A | Discretionary |
| Dec 12, 2022 | ZYME | $5.3K | Sale | 887 | $6.01 | Discretionary |